Introduction {#s1}
============

Prostate cancer (PCa) is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males according to the latest report released by the International Agency for Research on Cancer (IARC) in 2008 [@pone.0071968-Jemal1]. It has been well established that PCa is one of the pronounced geographically and ethnically related human malignancies, with a much higher incidence observed in the Western world than in Asian countries [@pone.0071968-Matsuda1]. Recently, accumulated evidence from genome-wide association studies (GWASs) suggests that more than 40 single nucleotide polymorphisms (SNPs) are associated with human PCa risk, some of which were also confirmed in Chinese male populations. However, almost all the candidate SNPs are reported to be in weak associations with PCa risk to date [@pone.0071968-Gudmundsson1]--[@pone.0071968-Stadler1]. Therefore, it is still not fully understood to what extent genetic factors and their interactions with environmental attributes may play a role in the etiology of PCa.

The phosphoinositide-3 kinase-AKT-mammalian target of rapamycin pathway (PI3K/AKT/mTOR) is a major pathway controlling cell growth and tumogenesis [@pone.0071968-Moore1], [@pone.0071968-Vivanco1]. As a key downstream effector of PI3K/AKT/mTOR pathway, the mTOR has been confirmed to be a central regulator of vital cellular processes, such as cell growth, proliferation, metabolism, migration, and apoptosis, based on the *in vivo* and *in vitro* investigations [@pone.0071968-Yang1]--[@pone.0071968-Patel1]. Structurally, mTOR contains several important domains across the whole protein, of these, the rapamycin-binding domain and the kinase domain was considered closely relevant to carcinogenesis [@pone.0071968-Zhou1]. Additionally, several studies have demonstrated that mTOR targeted therapies can be designed to block the induction of the proliferative, prosurvival, and oncogenic functions of *mTOR* [@pone.0071968-Hidalgo1]. Therefore, it was speculated that *mTOR* is a possible driver gene in carcinogenesis, and a promising target point and prognosis marker in cancer treatment as well.

Somatic aberrations of PI3K/AKT/mTOR pathway genes have been commonly observed in a variety of malignancies, including PCa [@pone.0071968-Vivanco1]. And the mutations in the *mTOR* gene have been identified in a few human cancers [@pone.0071968-Sato1]; however, the mechanism has not been well established to date. PCa harboring almost the same well-known mutations often presents with heterogeneous clinicpathologic characteristics. By the same token, genetic factors, such as naturally occurring polymorphic genetic variants or SNPs in *mTOR*, may be contributing to the variation in individual susceptibility to PCa and the progression of this disease.

Given that mTOR is one of the most important downstream components of the mTOR pathway, which can also receive signals from other pivotal pathways. Several studies have demonstrated that mTOR can serve as a promising therapeutic target in the future cancer treatment. And there have been few studies to date addressing the role of common, functional variants in the mTOR gene as PCa susceptibility factors, together with some variations of other pivotal genes in this pathway have been investigated as weak or null associations with cancer risk. we performed a case-control study by genotyping six potential functional SNPs in *mTOR* using genomic DNA from 1004 patients with prostate adenocarcinoma and 1051 cancer-free controls in an Eastern Chinese Han population. We tested the hypothesis that risk of PCa may be associated with SNPs in the *mTOR* gene and their interactions with environmental factors.

Materials and Methods {#s2}
=====================

Patients and controls {#s2a}
---------------------

We recruited PCa patients and the matched cancer-free controls from genetically unrelated Chinese Han participants between January 2008 and January 2012. This analysis included 1004 patients who were inhabitants of the administrative regions of eastern China (including Shanghai city, Zhejiang province, Jiangsu province and the surrounding areas) and have been histopathologically confirmed primary prostate adenocarcinoma at Fudan University Shanghai Cancer Center (FUSCC). All cases had received no prior chemotherapy or radiotherapy upon recruitment. The clinical stages were determined and categorized into stage I (T1a-bN0M0), stage II (T1c-2N0M0), stage III (T3-4N0M0), and stage IV (T1c-4N1M0-1 or T1-4N0-1M1) according to the Tumor-Node-Metastasis system, and pathological grades of the PCa were determined according to the WHO criteria [@pone.0071968-Ohori1]. The entire document, including the Gleason score, serum PSA level at diagnosis, and clinical staging (TNM) was abstracted from the archival medical records. The male control group was comprised of 1051 cancer-free individuals, frequency-matched with the cases by age (±5 years) and geographical regions, recruited from the Taizhou longitudinal study (TZL) [@pone.0071968-He1] during the same period. Individuals with a known test of serum PSA \>4 ng/mL present with or without abnormal digital rectal examination were excluded from the control group.

All of the participants were interviewed with a self-administered questionnaire after a written informed consent was obtained. Blood samples were collected and processed, with a written informed consent from participants, as a routine practice by the Institutional Tissue Bank at Shanghai Cancer Institute (for cases) and the TZL study (for controls). Response rate was 92% and 91% for cases and controls, respectively. The research was approved by the Institutional Review Board of FUSCC.

Single nucleotide polymorphisms selection {#s2b}
-----------------------------------------

Among all of the reported *mTOR* SNPs, potentially functional SNPs of interest were selected from the NCBI dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP>) and SNPinfo (<http://snpinfo.niehs.nih.gov/snpfunc.htm>) according to the following criteria: 1) the minor allele frequency (MAF) reported in HapMap was≥5% for Chinese populations; 2) affecting the functional regions of the gene, including transcription factor binding site (TFBS), potential miRNA binding site, splicing regulation locus, and stop codon; 3) the linkage disequilibrium (LD) coefficient *r* ^2^ \<0.8 between SNPs; and) not included in the published GWASs studies. Ultimately, six variants were selected for the present study, including rs2536 T\>C, rs1883965 G\>A, rs1034528 G\>C, rs17036508 T\>C, rs3806317 A\>G, and rs2295080 T\>G, of which four (rs1034528 G\>C, rs1883965 G\>A, rs2295080 T\>G, and rs3806317 A\>G) located in the first intron region may affect the transcription factor binding site (TFBS) activity, two (rs2536 T\>C and rs17036508 T\>C) located in the 3′-untranslated region (3′ UTR) region may affect the miRNA binding site activity, and SNP rs17036508 T\>C locus also predicted locate at the potential splicing site. Bioinformatics analysis was performed with HaploView software 4.2 to estimate the haplotype block for Chinese population (CHB) data of HapMap (HapMap Data Rel 27 Phase II+III), and no LD was found between any of these SNPs described above. All these six selected SNPs were genotyped by the TaqMan real-time PCR method as described previously [@pone.0071968-He1], and the results with \>98% call rates and 100% concordance for duplicated specimens were acceptable for further genotyping data analysis.

Multifactor Dimensionality Reduction (MDR) Analysis {#s2c}
---------------------------------------------------

Evidence indicated that gene--gene and gene--environment interactions are difficult to be fully characterized by using logistic regression model. And statistic power would decrease and type II errors would increase when detecting interactions by LR in case-control studies with relatively small sample sizes [@pone.0071968-Hahn1]. By contrast, The MDR analysis can overcomes some of the limitations of logistic regression model for the interactions by collapsing high-dimensional data into a single dimensional variable with two levels. In the present study, we performed the MDR analysis, as described previously [@pone.0071968-Ritchie1]. We used a model of 100-fold cross-validation and repeated the complete analysis for 10 times under different random seeds, and then the test was repeated 1000 times under the null hypothesis of no association. As a result, the model employing the minimized prediction error together with the maximized cross-validation consistency (CVC) was recommended. This analysis was performed by using the MDR V2.0 beta 8.2 software (<http://www.multifactordimensionalityreduction.org/>).

Statistical analysis {#s2d}
--------------------

Hardy-Weinberg equilibrium (HWE) for evaluation of genotype distributions of the controls was performed by a goodness-of fit χ^2^ test. Differences in the frequency distributions of the alleles, genotypes and the selected categorical variables between cases and controls were evaluated by Pearson\'s χ^2^ test under various genetic models (including dominant model, recessive model, and additive model). Crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated according to the significant genetic models by univariate and multivariate unconditional logistic regression models, respectively, to evaluate associations between the genotypes and risk of Pca with and without adjustment for by confounding factors. Given the present study was single ethnicity, and all of the SNPs loci were agree with HEW, the confounding factors which should be adjusted for was age, smoking status, and body mass index (BMI). Further stratification analyses were conducted to calculate the associations of SNP genotypes with PCa risk by demographic and clinic-pathologic variables, followed by the homogeneity Q-tests to detect any difference in the risk estimates between the strata. Based on the observed genotypes, haplotype frequencies and individual haplotypes were generated using Statistical Analysis Software PROC HAPLOTYPE, with a reference group of common haplotype, to calculate ORs for haplotypes associated with PCa risk in logistic regression analysis. For all the significant findings observed in our study, we calculated the false-positive report probability (FPRP) with prior probabilities of 0.0001, 0.001, 0.01, 0.1 and 0.25 to detect the possible false-positive associations [@pone.0071968-Wacholder1]. Statistical power was estimated to detect an OR of 1.50/0.67 (for a risk/protective effect), with an α level equal to the observed *P* value. Only significant results with FPRP value less than 0.2 were considered a noteworthy association. All statistical analyses were performed with SAS 9.1 statistical software (SAS, Cary, NC, USA). All *P* values were two-sided with a significance level of *P* \<0.05.

Results {#s3}
=======

Characteristics of the subjects {#s3a}
-------------------------------

The distributions of demographic characteristics of the subjects are presented in [**Table 1**](#pone-0071968-t001){ref-type="table"}. Briefly, there were no statistical differences in the distributions of age and smoking status between 1004 cases and 1051 controls. The body mass index (BMI) for overweight (\> 24.0 kg/m^2^) was more evident in controls than in cases (*P* \< 0.0001), which was further adjusted for in subsequent multivariate logistic regression analyses. Among the case subjects, 178 (17.7%) cases were PSA≤10 ng/ml, 312 (31.1%) cases were Gleason score≤7 (3+4), and 601 (59.9%) cases were Gleason score≥7 (4+3). For tumor staging, five (0.5%) cases had stage I disease, 431 (42.9%) had stage II disease, 140 (13.9%) had stage III disease, and 351 (35.0%) had stage IV disease. However, some cases had missing data because of the insufficient documented records, including 87 (8.7%) lacking serum PSA values, 91 (9.1%) lacking Gleason scores, and 77 (7.7%) lacking clinical staging status.

10.1371/journal.pone.0071968.t001

###### Distribution of demographic and clinical-pathologic characteristics of prostate cancer patients and cancer-free controls from Eastern Chinese men.
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  Variables            Cases No. (%)   Controls No. (%)   *P* [a](#nt102){ref-type="table-fn"}
  ------------------- --------------- ------------------ --------------------------------------
  All subjects          1004 (100)        1051 (100)     
  Age, yr (Mean±SD)      69.0±8.16        69.0±8.96                      0.141
  ≤69                   510 (50.8)        494 (49.2)     
  \>69                  568 (54.0)        483 (46.0)     
  BMI (kg/m^2^)                                                        \< 0.0001
  ≤24                   754 (75.1)        250 (24.9)     
  \>24                  637 (60.6)        414 (39.4)     
  Smoking status                                                         0.572
  Never                 402 (40.0)        602 (60.0)     
  Ever                  408 (38.8)        643 (61.2)     
  PSA value (ng/ml)                                      
  ≤10                   178 (17.7)                       
  10--20                193 (19.2)                       
  \>20                  546 (54.4)                       
  Missing                87 (8.7)                        
  Gleason score                                          
  ≤7(3+4)               312 (31.1)                       
  ≥7(4+3)               601 (59.9)                       
  Missing                91 (9.1)                        
  Stage of disease                                       
  I                       5 (0.5)                        
  II                    431 (42.9)                       
  III                   140 (13.9)                       
  IV                    351 (35.0)                       
  Missing                77 (7.7)                        

SD, standard deviation. BMI, body mass index.

Two-sided chi-square tests were used to calculate differences in the frequency distribution of genotypes between cases and controls.

The results were in bold, if *P*\<0.05.

The *mTOR* allele and genotype distributions and associations with PCa risk {#s3b}
---------------------------------------------------------------------------

The genotype and allele distributions of the six selected SNPs among cases and controls are summarized in [**Table 2**](#pone-0071968-t002){ref-type="table"}. The observed genotype frequencies of the six SNPs in controls agreed with the Hardy-Weinberg equilibrium. Furthermore, significant differences in genotype distributions were observed between cases and controls for rs2536 T\>C (*P* = 0.007), rs1034528 G\>C (*P* = 0.022), and rs2295080 T\>G (*P* = 0.012). Interestingly, the heterozygote genotypes of the above three SNPs were more likely to be significantly associated with PCa risk with adjusted OR (95% CI) and *P* value of 1.45 (1.15--1.84) and 0.002 for rs2536 TC, 1.31 (1.08--1.59) and 0.005 for rs1034528 GC, and 0.77 (0.64--0.93) and 0.006 for rs2295080 TG, respectively, compared with their respective wild-type genotypes, respectively. Additionally, we also found significant associations with PCa risk for SNPs in special genetic models, including rs2536 T\>C \[additive: adjusted OR = 1.34 (1.08--1.66), *P* = 0.008; dominant: adjusted OR = 1.42 (1.13--1.78), *P* = 0.003\]; rs1034528 G\>C \[additive: adjusted OR = 1.21 (1.03--1.42), *P* = 0.019; dominant: adjusted OR = 1.29 (1.07--1.55), *P* = 0.007\]; and rs2295080 T\>G \[additive: adjusted OR = 0.80 (0.69--0.94), *P = *0.005; dominant: adjusted OR = 0.76 (0.64--0.92), *P = *0.003\]. Further analyses of the combined genotypes of these six SNPs revealed a significant increase in PCa risk with increasing numbers of putative high-risk alleles (*P* ~trend~ = 0.0005) ([**Table 3**](#pone-0071968-t003){ref-type="table"}).

10.1371/journal.pone.0071968.t002

###### Logistic regression analysis of associations between *mTOR* genotypes and prostate cancer risk in Eastern Chinese men.
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  Variables (HWE)[a](#nt105){ref-type="table-fn"}    Cases (N = 1004)   Controls (N = 1051)   *P* [b](#nt106){ref-type="table-fn"}     Crude OR (95% CI)              *P*            Adjusted OR (95% CI)[b](#nt106){ref-type="table-fn"}   *P* [c](#nt107){ref-type="table-fn"}
  ------------------------------------------------- ------------------ --------------------- -------------------------------------- ----------------------- ----------------------- ------------------------------------------------------ --------------------------------------
  **rs2536 (HWE: *P* = 0.156)**                                                                                                                                                                                                            
  TT                                                    804 (80.1)          894 (85.1)                       0.007                           1.00                                                            1.00                          
  CT                                                    192 (19.1)          147 (14.0)                                               **1.45 (1.15--1.84)**         **0.002**                        **1.45 (1.15--1.84)**                                **0.002**
  CC                                                     8 (0.8)             10 (0.9)                                                  0.89 (0.35--2.27)             0.806                            0.88 (0.35--2.25)                                    0.795
  Additive model                                                                                     **1.34 (1.08--1.66)**                 **0.008**         **1.34 (1.08--1.66)**                        **0.008**                        
  Dominant model                                                               0.003                 **1.42 (1.13--1.78)**                 **0.003**         **1.42 (1.13--1.78)**                        **0.003**                        
  Recessive model                                                              0.707                   0.84 (0.33--2.13)                     0.709             0.83 (0.33--2.12)                            0.698                          
  **rs1883965 (HWE: *P* = 0.904)**                                                                                                                                                                                                         
  GG                                                    843 (84.0)          890 (84.7)                       0.874                           1.00                                                            1.00                          
  AG                                                    153 (15.2)          154 (14.7)                                                 1.05 (0.82--1.34)             0.700                            1.06 (0.83--1.35)                                    0.640
  AA                                                     8 (0.8)              7 (0.7)                                                  1.21 (0.44--3.34)             0.718                            1.33 (0.48--3.70)                                    0.588
  Additive model                                                                                       1.06 (0.85--1.32)                     0.622             1.08 (0.86--1.34)                            0.522                          
  Dominant model                                                               0.655                   1.06 (0.83--1.34)                     0.655             1.07 (0.84--1.36)                            0.574                          
  Recessive model                                                              0.728                   1.20 (0.43--3.32)                     0.728             1.32 (0.47--3.66)                            0.600                          
  **rs1034528 (HWE: *P* = 0.443)**                                                                                                                                                                                                         
  GG                                                    639 (63.7)          727 (69.2)                       0.022                           1.00                                                            1.00                          
  CG                                                    333 (33.2)          290 (27.6)                                               **1.31 (1.08--1.58)**         **0.006**                        **1.31 (1.08--1.59)**                                **0.005**
  CC                                                     32 (3.2)            34 (3.2)                                                  1.07 (0.65--1.76)             0.787                            1.09 (0.66--1.79)                                    0.739
  Additive model                                                                                     **1.20 (1.03--1.41)**                 **0.023**         **1.21 (1.03--1.42)**                        **0.019**                        
  Dominant model                                                               0.008                 **1.28 (1.07--1.54)**                 **0.008**         **1.29 (1.07--1.55)**                        **0.007**                        
  Recessive model                                                              0.951                   0.99 (0.60--1.61)                     0.951             1.00 (0.61--1.64)                            0.994                          
  **rs17036508 (HWE: *P* = 0.085)**                                                                                                                                                                                                        
  TT                                                    749 (74.6)          820 (78.0)                       0.135                           1.00                                                            1.00                          
  CT                                                    237 (23.6)          210 (20.0)                                                 1.24 (1.00--1.53)             0.049                            1.23 (0.99--1.52)                                    0.055
  CC                                                     18 (1.8)            21 (2.0)                                                  0.94 (0.50--1.78)             0.846                            0.94 (0.49--1.77)                                    0.839
  Additive model                                                                                       1.15 (0.96--1.38)                     0.128             1.15 (0.96--1.38)                            0.139                          
  Dominant model                                                               0.068                   1.21 (0.99--1.48)                     0.069             1.20 (0.98--1.48)                            0.076                          
  Recessive model                                                              0.733                    0.90 (0.47-1.69)                     0.734             0.89 (0.47--1.69)                            0.731                          
  **rs3806317 (HWE: *P* = 0.746)**                                                                                                                                                                                                         
  AA                                                    772 (76.9)          790 (75.2)                       0.351                           1.00                                                            1.00                          
  AG                                                    220 (21.9)          241 (22.9)                                                 0.93 (0.76--1.15)             0.521                            0.93 (0.76--1.15)                                    0.500
  GG                                                     12 (1.2)            20 (1.9)                                                  0.61 (0.30--1.27)             0.186                            0.61 (0.29--1.25)                                    0.174
  Additive model                                                                                       0.90 (0.75--1.08)                     0.242             0.89 (0.74--1.07)                            0.224                          
  Dominant model                                                               0.360                   0.91 (0.74--1.11)                     0.360             0.91 (0.74--1.11)                            0.340                          
  Recessive model                                                              0.195                   0.62 (0.30--1.28)                     0.199             0.62 (0.30--1.27)                            0.188                          
  **rs2295080 (HWE: *P* = 0.334)**                                                                                                                                                                                                         
  TT                                                    653 (65.0)          617 (58.7)                       0.012                           1.00                                                            1.00                          
  GT                                                    311 (31.0)          382 (36.4)                                               **0.77 (0.64--0.93)**         **0.006**                        **0.77 (0.64--0.93)**                                **0.006**
  GG                                                     40 (4.0)            52 (5.0)                                                  0.73 (0.47--1.11)             0.143                            0.73 (0.48--1.12)                                    0.147
  Additive model                                                                                     **0.80 (0.69--0.93)**                 **0.004**         **0.80 (0.69--0.94)**                        **0.005**                        
  Dominant model                                                               0.003                 **0.76 (0.64--0.91)**                 **0.003**         **0.76 (0.64--0.92)**                        **0.003**                        
  Recessive model                                                              0.291                   0.80 (0.52--1.22)                     0.292             0.8 (0.52--1.22)                             0.300                          

OR, odds ratio; CI, confidence interval.

Hard-Wenberg equilibrium test for controls.

Two-sided Chi-square tests were used to calculate differences in the frequency distribution of genotypes between cases and controls.

Adjusted for age, smoking, and BMI status in logistic regress models.

The results were in bold, if the 95% CI excluded 1 or *P* \<0.05.

10.1371/journal.pone.0071968.t003

###### Combined effects of risk genotypes of *mTOR* by dominant genetic models.
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  *mTOR* Variables      Cases       Controls    *P* [a](#nt109){ref-type="table-fn"}         Crude OR             *P*                    Adjusted OR                  *P* [b](#nt110){ref-type="table-fn"}
  ------------------ ------------ ------------ -------------------------------------- ----------------------- ----------- ------------------------------------------ --------------------------------------
  Genotypes           (N = 1004)   (N = 1051)                                                (95% CI)                      (95% CI)[a](#nt109){ref-type="table-fn"}  
  0--1                466 (46.4)   543 (51.7)                  0.004                           1.00                                          1.00                    
  2                   295 (29.4)   322 (30.6)                                            1.07 (0.87--1.31)       0.523                1.07 (0.87--1.31)                              0.516
  3                   162 (16.1)   129 (12.3)                                          **1.46 (1.13--1.90)**   **0.004**            **1.48 (1.14--1.93)**                          **0.004**
  4                    79 (7.9)     53 (5.0)                                           **1.74 (1.20--2.51)**   **0.003**            **1.74 (1.20--2.52)**                          **0.003**
  5                    2 (0.2)      4 (0.4)                                              0.58 (0.11--3.20)       0.534                0.52 (0.09--2.86)                              0.450
                                                                                                                                     *P* ~trend~ = 0.0005            
  0--1                466 (46.4)   543 (51.7)                  0.017                           1.00                                          1.00                    
  ≥2                  538 (53.6)   508 (48.3)                    ?                     **1.23 (1.04--1.47)**   **0.018**            **1.24 (1.04--1.47)**                          **0.016**

Chi-square test was used to calculate the genotype frequency distributions.

Obtained under dominant models in logistic regression analyses with adjustment for age, smoking status and BMI.

The results were in bold, if the 95% CI excluded 1 or *P*\<0.05.

Stratification analysis of PCa risk associated with *mTOR* SNPs {#s3c}
---------------------------------------------------------------

In stratification analyses, as shown in [**Tables 4**](#pone-0071968-t004){ref-type="table"} and [**5**](#pone-0071968-t005){ref-type="table"}, the multivariate logistic regression analyses indicated, by assuming a dominant genetic model, that both *mTOR* rs2536 CT/CC and rs1034528 CG/CC genotypes were associated with an increased risk of PCa, particularly in subgroups of age≤69, BMI≤24 kg/m^2^, ever smokers, Gleason score≤7 (3+4), Gleason score≥7 (3+4), and stage III/IV disease, compared with their homozygous wild-type genotypes, respectively. The rs17036508 CT/CC genotypes were also associated with an increased risk of PCa among subgroups of BMI≤24 kg/m^2^, Gleason score≤7 (3+4), and stage III+IV diseases, compared with the TT homozygous variant genotype. In contrast, the rs2295080 GT/TT genotypes had a protective effect, particularly in subgroups of age\>69, BMI, ever smokers, Gleason score≥7 (3+4), and stage I+II diseases, compared with the GG homozygous variant genotype. However, further homogeneity tests indicated that there was no difference in risk estimates between subgroups for most of the strata with a few exceptions including BMI level by rs2536 CT/CC genotypes \[OR = 1.43 (1.13--1.80), *P* = 0.017\] and by rs1034528 CC/CG genotypes \[OR = 1.28 (1.07--1.55), *P* = 0.039\]; disease stage by rs2536 CT/CC genotypes \[OR = 1.47 (1.20--1.80), *P* = 0.004\] and by rs17036508 CT/CC genotypes \[OR = 1.24 (1.04--1.49), *P* = 0.024\].

10.1371/journal.pone.0071968.t004

###### Stratification analysis for associations between *mTOR* variants and prostate cancer risk by dominant genetic models in all subjects of Eastern Chinese men.
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  Variables              rs2536    Adjusted   *P* [a](#nt113){ref-type="table-fn"}    *P* ^hom^     rs1883965   Adjusted   *P* [a](#nt113){ref-type="table-fn"}       *P* ^hom^       rs1034528   Adjusted   *P* [a](#nt113){ref-type="table-fn"}   *P* ^hom^                                       
  --------------------- --------- ---------- -------------------------------------- -------------- ----------- ---------- -------------------------------------- ------------------- ----------- ---------- -------------------------------------- ----------- ----------------------- ------------ -------
  Age, yr (median)                                                                                                                                                                                                                                                                                  
  ≤69                    103/84    407/484           **1.42 (1.03--1.95)**            **0.031**       0.796      90/88                   420/480                  1.19 (0.86--1.65)     0.291      0.378                   189/167                   321/401    **1.40 (1.09--1.81)**   **0.010**    0.269
  \>69                    97/73    397/410             1.38 (0.99--1.93)                0.057                    71/73                   423/410                  0.94 (0.66--1.34)     0.716                              176/157                   318/326      1.16 (0.89--1.51)       0.287     
  BMI, kg/m^2^                                                                                                                                                                                                                                                                                      
  ≤24                    159/85    595/552           **1.74 (1.30--2.32)**            **0.0002**    **0.017**    117/95                  637/542                  1.05 (0.79--1.42)     0.726      0.782                   284/186                   470/451    **1.47 (1.17--1.84)**   **0.001**    0.039
  \>24                    41/72    209/342             0.93 (0.61--1.41)                0.736                    44/66                   206/348                  1.13 (0.74--1.71)     0.578                               81/138                   169/276      0.95 (0.68--1.33)       0.776     
  Smoking status                                                                                                                                                                                                                                                                                    
  Never                   82/63    320/345             1.40 (0.98--2.02)                0.068         0.951      60/66                   342/342                  0.93 (0.63--1.36)     0.701      0.322                   149/132                   253/276      1.24 (0.93--1.66)       0.144      0.733
  Ever                   118/94    484/549           **1.42 (1.06--1.92)**            **0.021**                  101/95                  501/548                  1.18 (0.87--1.60)     0.298                              216/192                   386/451    **1.32 (1.04--1.67)**   **0.023**   
  Gleason score^b^                                                                                                                                                                                                                                                                                  
  ≤7(3+4)                67/157    245/894           **1.58 (1.15--2.18)**            **0.005**       0.699      56/161                  256/890                  1.24 (0.89--1.74)     0.208      0.562                   124/324                   188/727    **1.51 (1.16--1.96)**   **0.002**    0.438
  ≥7(4+3)                121/157   480/894           **1.44 (1.11--1.87)**            **0.007**                  97/161                  504/890                  1.07 (0.81--1.41)     0.635                              220/324                   381/727    **1.30 (1.05--1.60)**   **0.016**   
  Stage of disease^c^                                                                                                                                                                                                                                                                               
  I+II                   68/157    368/894             1.07 (0.78--1.46)                0.672       **0.004**    79/161                  357/890                  1.25 (0.93--1.68)     0.142      0.339                   147/324                   289/727      1.16 (0.92--1.48)       0.214      0.078
  III+IV                 123/157   368/894           **1.91 (1.47--2.49)**           **\<0.0001**                75/161                  416/890                  1.00 (0.75--1.35)     0.980                              199/324                   292/727    **1.53 (1.22--1.91)**   **0.0002**  

  Variables              rs17036508   Adjusted   *P* [a](#nt113){ref-type="table-fn"}   *P* ^hom^   rs3806317   Adjusted   *P* [a](#nt113){ref-type="table-fn"}       *P* ^hom^       rs2295080   Adjusted   *P* [a](#nt113){ref-type="table-fn"}   *P* ^hom^                                      
  --------------------- ------------ ---------- -------------------------------------- ----------- ----------- ---------- -------------------------------------- ------------------- ----------- ---------- -------------------------------------- ----------- ----------------------- ----------- -------
  Age, yr (median)                                                                                                                                                                                                                                                                                 
  ≤69                     129/120     381/448             1.23 (0.92--1.63)               0.161       0.642     113/140                  397/428                  0.86 (0.65--1.14)     0.296      0.674                   195/247                   315/321      0.79 (0.62--1.01)       0.055     0.599
  \>69                    126/111     368/372             1.16 (0.87--1.56)               0.320                 119/121                  375/362                  0.94 (0.70--1.25)     0.659                              156/187                   338/296    **0.74 (0.57--0.96)**   **0.024**  
  BMI, kg/m^2^                                                                                                                                                                                                                                                                                     
  ≤24                     200/139     554/498           **1.29 (1.01--1.66)**           **0.042**     0.242     172/164                  582/473                  0.85 (0.67--1.09)     0.206      0.398                   271/265                   483/372    **0.79 (0.64--0.98)**   **0.035**   0.476
  \>24                     55/92      195/322             0.98 (0.67--1.43)               0.918                  60/97                   190/317                  1.03 (0.71--1.48)     0.896                               80/169                   170/245    **0.68 (0.49--0.94)**   **0.021**  
  Smoking status                                                                                                                                                                                                                                                                                   
  Never                    108/96     294/312             1.19 (0.86--1.63)               0.288       0.932      98/103                  304/305                  0.95 (0.69--1.31)     0.747      0.695                   152/173                   250/235      0.83 (0.62--1.10)       0.187     0.473
  Ever                    147/135     455/508             1.21 (0.93--1.58)               0.165                 134/158                  468/485                  0.86 (0.66--1.12)     0.262                              199/261                   403/382    **0.72 (0.57--0.91)**   **0.006**  
  Gleason score^b^                                                                                                                                                                                                                                                                                 
  ≤7(3+4)                  90/231     222/820           **1.44 (1.08--1.92)**           **0.013**     0.253      75/261                  237/790                  0.95 (0.71--1.27)     0.720      0.480                   121/434                   191/617      0.91 (0.70--1.18)       0.465     0.289
  ≥7(4+3)                 148/231     453/820             1.16 (0.92--1.47)               0.219                 130/261                  471/790                  0.84 (0.66--1.06)     0.140                              208/434                   393/617    **0.75 (0.61--0.93)**   **0.008**  
  Stage of disease^c^                                                                                                                                                                                                                                                                              
  I+II                     95/231     341/820             1.00 (0.76--1.31)               0.970     **0.024**   101/261                  335/790                  0.90 (0.69--1.17)     0.439      0.628                   142/434                   294/617    **0.69 (0.55--0.88)**   **0.002**   0.092
  III+ IV                 146/231     345/820           **1.50 (1.18--1.91)**           **0.001**               106/261                  385/790                  0.83 (0.64--1.08)     0.158                              191/434                   300/617      0.90 (0.73--1.13)       0.364    

BMI, body mass index.

Obtained under dominant models in logistic regression analyses with adjustment for age, smoking status and BMI.

According to the current WHO recommendations.

*P* ^hom^ *P* value for homogeneiy test.

The results were in bold, if *P*\<0.05.

10.1371/journal.pone.0071968.t005

###### Stratification analysis for associations between combined risk genotypes of *mTOR* variants and prostate cancer risk.
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  Variables           Combined effect of risk genotypes (cases/controls)   Crude OR(95%CI)          *P*          Adjusted OR(95%CI)[a](#nt117){ref-type="table-fn"}   *P* [a](#nt117){ref-type="table-fn"}   *P* [b](#nt118){ref-type="table-fn"}   Interaction  
  ------------------ ---------------------------------------------------- ----------------- ------------------- ---------------------------------------------------- -------------------------------------- -------------------------------------- ------------- -------
  Age, yr                                                                                                                                                                                                                                                        
  ≤69 (median)                             236/301                             274/267       1.31 (1.03--1.66)                         0.028                                 **1.29 (1.02--1.65)**                        **0.036**                    0.473      0.872
  \>69 (median)                            230/242                             264/241       1.15 (0.90--1.48)                         0.268                                   1.15 (0.90--1.48)                            0.271                                
  BMI, kg/m^2^                                                                                                                                                                                                                                                   
  ≤24                                      348/336                             406/301       1.30 (1.05--1.61)                         0.014                                 **1.31 (1.06--1.61)**                        **0.013**                    0.431      0.431
  \>24                                     118/207                             132/207       1.12 (0.82--1.53)                         0.484                                   1.11 (0.81--1.52)                            0.527                                
  Smoking status                                                                                                                                                                                                                                                 
  Never                                    185/201                             217/207       1.14 (0.86--1.50)                         0.356                                   1.15 (0.87--1.52)                            0.322                      0.470      0.470
  Ever                                     281/342                             321/301       1.30 (1.04--1.62)                         0.022                                 **1.29 (1.03--1.61)**                        **0.027**                              
  Gleason score                                                                                                                                                                                                                                                  
  ≤7(3+4)                                  133/543                             179/508       1.44 (1.12--1.86)                         0.005                                 **1.46 (1.13--1.89)**                        **0.004**                    0.258     
  ≥7(4+3)                                  284/543                             317/508       1.19 (0.98--1.46)                         0.085                                   1.19 (0.98--1.46)                            0.084                                
  Stage of disease                                                                                                                                                                                                                                               
  I+II                                     208/543                             228/508       1.17 (0.94--1.47)                         0.165                                   1.18 (0.95--1.48)                            0.140                      0.400     
  III+ IV                                  218/543                             273/508       1.34 (1.08--1.66)                         0.008                                 **1.34 (1.08--1.66)**                        **0.008**                              

Obtained in logistic dominant models with adjustment for age, smoking status and BMI.

*P* for homogeneity test using the χ2-based Q test.

Test for multiplicative interaction obtained from logistic regression models with adjustment for age, smoking status and BMI.

CI, confidence interval; BMI, body mass index.

The results were in bold, if *P*\<0.05.

Haplotype analysis of the *mTOR* SNPs {#s3d}
-------------------------------------

Based on the genotyping results to infer possible haplotypes, we used the four SNPs (rs2536 T\>C, rs1034528 G\>C, rs17036508 T\>C, and rs2295080 T\>G) that were statistically significantly associated with PCa risk in the single locus analysis ([**Table 6**](#pone-0071968-t006){ref-type="table"}). When the common "TGTT" haplotype was used as the reference, the "CCCG" haplotype was associated with an evidently increased PCa risk \[adjusted OR = 1.31 (1.03--1.66), *P = *0.026\] However, the "TGTG" and "TGCG" haplotypes were associated with an evidently decreased but not increased PCa risk, with the adjusted OR of 0.39 (0.27--0.56), *P* \<0.0001 and 0.63 (0.43--0.91), *P = *0.014, respectively. The findings of haplotypes "CCTG" and "CCCT" may not be reliable due to their relatively small numbers of observations.

10.1371/journal.pone.0071968.t006

###### The frequency of common inferred haplotrypes of the *mTOR* gene based on the observed genotypes.
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  rs2536    rs1034528   rs17036508   rs2295080   Case (N = 2014)   Control (N = 2134)   Adjusted OR (95% CI)   *P* [a](#nt122){ref-type="table-fn"}
  -------- ----------- ------------ ----------- ----------------- -------------------- ---------------------- --------------------------------------
  T             G           T            T            1515                1572                  1.00          
  T             G           T            G             41                 109            0.39 (0.27--0.56)                   \<0.000
  T             G           C            T             12                  7             1.77 (0.70--4.51)                    0.231
  T             G           C            G             46                  76            0.63 (0.43--0.91)                    0.014
  T             C           T            T             55                  40            1.44 (0.95--2.17)                    0.087
  T             C           T            G             127                145            0.92 (0.71--1.17)                    0.481
  T             C           C            T              3                  2             1.48 (0.24--8.90)                    0.667
  T             C           C            G              6                  14            0.43 (0.16--1.11)                    0.081
  C             G           T            T              0                  2                     \-                             \-
  C             G           T            G              0                  2                     \-                             \-
  C             G           C            T              0                  1                     \-                             \-
  C             G           C            G              0                  2                     \-                             \-
  C             C           T            T              1                  2             0.55 (0.05--6.03)                    0.622
  C             C           T            G              1                  9             0.11 (0.01--0.89)                    0.039
  C             C           C            T             36                  15            2.47 (1.34--4.52)                    0.004
  C             C           C            G             171                136            1.31 (1.03--1.66)                    0.026
                                                                                                              

Obtained under dominant models in logistic regression analyses with adjustment for age, smoking status and BMI.

The results were in bold, if the 95% CI excluded 1 or *P*\<0.05.

Association of high-order interactions with PCa {#s3e}
-----------------------------------------------

To further explore high-order interactions, we performed the MDR analyses by including the genotypes of four significant *mTOR* SNPs (i.e., rs2536 CT/CC, rs1034528 CG/CC, rs17036508 CT/CC, and rs2295080 GT/GG vs. their wild-type homozygotes, respectively) and three risk factors (i.e., age at diagnosis, smoking status, and BMI). The results showed that BMI was the best one-factor model with the highest CVC (100%) and the lowest prediction error (42.7%) among all seven factors. Likewise, the interaction between BMI, rs17036508 T\>C, and rs2536 T\>C was the best three-factor model involving both environmental and genetic factors with the highest CVC (100%) and the lowest prediction error of 41.9% ([**Table 7**](#pone-0071968-t007){ref-type="table"}).

10.1371/journal.pone.0071968.t007

###### MDR analysis for the risk of prostate cancer prediction in an Eastern Chinese population.
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  est interaction models                                                Cross-validation   Average prediction error   *P*-value[a](#nt126){ref-type="table-fn"}
  -------------------------------------------------------------------- ------------------ -------------------------- -------------------------------------------
  BMI                                                                       100/100                 42.7%                             \<0.0001
  BMI, rs2295080                                                            100/100                 42.7%                             \<0.0001
  **BMI, rs17036508, rs2536**                                             **100/100**             **41.9%**                         **\<0.0001**
  BMI, rs17036508, rs2536, rs2295080                                         99/100                 41.5%                             \<0.0001
  BMI, rs17036508, rs2536, rs2295080, smoking status                         95/100                 41.1%                             \<0.0001
  BMI, rs17036508, rs2536, rs2295080, smoking status, age                    90/100                 40.7%                             \<0.0001
  BMI, rs17036508, rs2536, rs2295080, rs1034528, smoking status, age         99/100                 40.2%                             \<0.0001

MDR, multifactor dimensionality reduction.

The best model with maximum cross-validation consistency and minimum prediction error rate was in bold.

*P*-value for 1000-fold permutation test.

Finally, the FPRP values at different prior probability levels for all significant findings are summarized in [**Table 8**](#pone-0071968-t008){ref-type="table"}. When the assumption of prior probability was 0.01, the association with rs2536 (CT/CC vs. TT) was noteworthy in subgroups of≤24 kg/m^2^ BMI and stage III+IV (FPRP = 0.112 and 0.055, respectively), and the similar results can be observed in the association with rs1034528 (CG/CC vs. GG) in subgroups of≤24 kg/m^2^ BMI and stage III+IV (FPRP = 0.132 and 0.043, respectively) as well as the association with subgroup of stage III+IV (FPRP = 0.165) by rs17036508 (CT/CC vs. TT). In contrast, some greater FPRP values for the other significant associations between *mTOR* variants and prostate cancer risk suggested some possible bias in the findings, which need further validation in larger studies.

10.1371/journal.pone.0071968.t008

###### False-positive report probability values for associations between the risk of cancer and the frequency of genotypes of *mTOR* variants.
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  mTOR SNP genotype                                          Crude OR (95%CI)    *P* [a](#nt128){ref-type="table-fn"}   Statistical power[b](#nt129){ref-type="table-fn"}   Prior probability                                  
  --------------------------------------------------------- ------------------- -------------------------------------- --------------------------------------------------- ------------------- ----------- ----------- ------- -------
  All patients                                                                                                                                                                                                                 
  rs2536, CT vs TT                                           1.45 (1.15--1.84)                  0.0018                                        0.614                             **0.009**       **0.026**     0.225     0.746   0.967
  rs1034528, CG vs GG                                        1.31 (1.08--1.58)                  0.0058                                        0.93                              **0.018**       **0.053**     0.382     0.862   0.984
  rs2295080, GT vs TT                                        1.24 (1.03--1.49)                  0.0203                                        0.982                             **0.058**       **0.157**     0.672     0.954   0.995
  rs2295080, GG vs TT                                        0.09 (0.02--0.30)                  0.0001                                        0.007                             **0.044**       **0.12**      0.601     0.938   0.993
  rs2295080, GG vs GT/TT                                     0.09 (0.03--0.28)                  0.0001                                        0.008                             **0.036**       **0.101**     0.552     0.926   0.992
  rs2536, CT/CC vs TT                                                                                                                                                                                                          
  All patients                                               1.42 (1.13--1.78)                  0.0029                                        0.699                             **0.012**       **0.036**     0.291     0.806   0.976
  Age≤69 yrs                                                 1.46 (1.06--2.00)                  0.0192                                        0.573                             **0.091**         0.232       0.768     0.971   0.997
  BMI≤24 kg/m^2^                                             1.74 (1.30--231)                   0.0002                                        0.157                             **0.004**       **0.011**   **0.112**   0.559   0.927
  Ever smoking                                               1.42 (1.06--1.92)                  0.0194                                        0.642                             **0.083**         0.214       0.749     0.968   0.997
  Gleason score≤7(3+4)                                       1.56 (1.13--2.14)                  0.0062                                        0.406                             **0.044**       **0.121**     0.602     0.938   0.993
  Gleason score≥7(4+3)                                       1.44 (1.11--1.87)                  0.0066                                        0.634                             **0.030**       **0.086**     0.507     0.912   0.990
  Stage III+ IV                                              1.90 (1.46--2.48)                  0.0001                                        0.17                              **0.002**       **0.005**   **0.055**   0.371   0.855
  rs1034528, CG/CC vs GG                                                                                                                                                                                                       
  All patients                                               1.28 (1.07--1.54)                  0.0080                                        0.958                             **0.024**       **0.07**      0.452     0.893   0.988
  Age≤69 yrs                                                 1.41 (1.10--1.82)                  0.0076                                        0.681                             **0.032**       **0.091**     0.525     0.918   0.991
  BMI≤24 kg/m^2^                                             1.47 (1.17--1.84)                  0.0009                                        0.586                             **0.005**       **0.014**   **0.132**   0.605   0.939
  Ever smoking                                               1.31 (1.04--1.67)                  0.0237                                        0.870                             **0.076**       **0.197**     0.730     0.965   0.996
  Gleason score≤7(3+4)                                       1.48 (1.14--1.92)                  0.0032                                        0.539                             **0.017**       **0.051**     0.370     0.856   0.983
  Gleason score≥7(4+3)                                       1.30 (1.05--1.60)                  0.0162                                        0.917                             **0.050**       **0.137**     0.636     0.946   0.994
  Stage III+ IV                                              1.53 (1.22--1.91)                  0.0002                                        0.443                             **0.001**       **0.004**   **0.043**   0.311   0.819
  rs17036508, CT/CC vs TT                                                                                                                                                                                                      
  BMI≤24 kg/m^2^                                             1.29 (1.01--1.66)                  0.0417                                        0.892                             **0.123**         0.296       0.822     0.979   0.998
  Gleason score≤7(3+4)                                       1.44 (1.08--1.91)                  0.0121                                        0.615                             **0.056**       **0.151**     0.661     0.952   0.995
  Stage III+ IV                                              1.50 (1.18--1.91)                  0.0010                                        0.499                             **0.006**       **0.018**   **0.165**   0.667   0.952
  rs2295080, GT/GG vs TT                                                                                                                                                                                                       
  Age≤69 yrs                                                 1.30 (1.01--1.66)                  0.0380                                        0.885                             **0.114**         0.279       0.810     0.977   0.998
  Gleason score≤7(3+4)                                       1.34 (1.03--1.73)                  0.0274                                        0.815                             **0.092**         0.232       0.769     0.971   0.997
  Stage III+ IV                                              1.35 (1.08--1.68)                  0.0074                                        0.885                             **0.024**       **0.070**     0.453     0.893   0.988
  Combined effect                                                                                                                                                                                                              
  4 variable genotypes                                       1.23 (1.04--1.47)                  0.017                                         0.988                             **0.052**       **0.141**     0.643     0.948   0.995
  mTOR haplotypes (rs2536-rs1034528-rs17036508-rs2295080)                                                                                                                                                                      
  T-G-T-G                                                    0.39 (0.27--0.56)                 \<0.0001                                       0.088                             **0.003**       **0.010**   **0.101**   0.531   0.919
  T-G-C-G                                                    0.63 (0.43--0.91)                  0.0137                                        0.378                             **0.098**         0.246       0.782     0.973   0.997
  C-C-C-G                                                    1.31 (1.03--1.65)                  0.0269                                        0.895                             **0.083**         0.213       0.748     0.968   0.997

OR, odds ratio; CI, confidence interval; BMI, body mass index.

Chi-square test was used to calculate the genotype frequency distributions.

Statistical power was calculated using the number of observations in the subgroup and the OR and *P* values in this table.

The results in false-positive report probability analysis were in bold, if the prior probability \< 0.2.

Discussion {#s4}
==========

In this large, ethnic specific single institutional case-control study, we investigated the associations between six potentially functional SNPs of the *mTOR* gene and PCa risk, and we found that the rs2536 C, rs1034528 C, and rs2295080 G variant genotypes were associated with PCa risk, and the effects were more evident in subgroups of age≤69, BMI≤24 kg/m^2^, and ever-smokers. Additionally, the variant genotypes were more common in patients with high-grade diseases (stage III+IV), indicating their likely involvement in the development and progression of PCa. To the best of our knowledge, this is the first post-GWAS study that focused on the associations of these six potentially functional *mTOR* SNPs with PCa risk.

The *mTOR* gene, located on chromosome 1p36.2, encodes a protein kinase product of 289 kDa and has emerged as a critical cell growth effector by controlling mRNA translation, ribosome biogenesis, autophagy, and metabolism [@pone.0071968-Guertin1]--[@pone.0071968-Wullschleger1]. Studies have shown that there are some important domains ranging from the *N*- to the *C*-terminus of mTOR. For example, the *N*-terminus of mTOR contains two tandem repeated HEAT motifs that can mediate interactions between proteins, the FAT domain that can facilitate focal adhesion to the targeting domain, and the FRB domain that is regarded as one high-affinity binding site for the inhibitory complex FKBP12-rapamycin, whereas there are two regulatory domains that are located at the *C*-terminus of the protein including PtdIns 3-kinase related catalytic domain and FATC domain [@pone.0071968-Zhou1]. To date, there are 2651 SNPs that have been observed scattered across the whole *mTOR* gene. Given the critical role of mTOR in the PNET/AKT/mTOR signaling pathway, it is biologically plausible that functional SNPs affecting the pivotal domains described above may contribute to cancer susceptibility. However, in addition to the published GWAS studies, only a few reported post-GWAS studies have investigated the associations between functional SNPs of the *mTOR* gene and risk of PCa. In a Chinese study with 666 PCa and 708 cancer-free controls, Chen et al. [@pone.0071968-Chen1] indicated that *mTOR* rs2295080 GT/GG genotypes had a protective effect on PCa risk, compared with the TT genotype, which was recently shown by Xu et al. in gastric cancer [@pone.0071968-Xu1] and by Cao et al. in renal cell cancer [@pone.0071968-Cao1]. These findings are consistent with those of the present study with a larger sample size. Additionally, Hildebrandt et al. found that individuals carrying the rs2295080 GG genotype had reversed clinical outcomes in Caucasian esophageal cancer patients treated with chemotherapy, compared with the TT homozygous wild-type genotype [@pone.0071968-Hildebrandt1]. All studies that focused on Chinese populations indicated an association between rs2295080 GT/GG and cancer risk, suggesting an possibly ethnic-specific association. Nevertheless, the associations between *mTOR* rs2536 C variant or genotypes and cancer risk in Chinese populations were various in the literatures; for example, the *mTOR* rs2536 CT heterozygous genotype was found to be associated with decreased risk of Chinese childhood acute lymphoblastic leukemia [@pone.0071968-Huang1]; however, this association was not observed in other tumor types, such as gastric cancer [@pone.0071968-He2], prostate cancer [@pone.0071968-Chen1], and esophageal squamous cell carcinoma [@pone.0071968-Zhu1]. On the contrary, in the present study, we found that the *mTOR* rs2536 CT/CC genotypes were associated with an increased PCa risk under a dominant genetic model, different from the findings of another previously published PCa study (666 cases and 708 controls), in which a null association was reported [@pone.0071968-Chen1]. We speculated that the disagreement might be due to the different sample size or different inclusion criteria for the participaion, which needs large and better designed studies to confirm.

Studies have shown that the rs2295080 T allele could enhance the transcription activity of *mTOR* in HEK293, 786-O, HeLa, and GES-1 cell line *in vitro* [@pone.0071968-Xu1], [@pone.0071968-Cao1]. Likewise, individuals carrying the TT genotype had higher levels of *mTOR* expression as well [@pone.0071968-Xu1], [@pone.0071968-Cao1]. These suggest that the rs2295080 T allele could increase the affinity of special transcription factors to this region of the *mTOR* promoter and subsequently contribute to the increased *mTOR* activity in humans. Theoretically, miRNAs can bind to the 3′ UTR of target genes and inhibit gene expression translationally and/or by destabilizing the target mRNA. Based on a bioinformatics web server (<http://snpinfo.niehs.nih.gov/cgi-bin/snpinfo>), the SNP rs2536 T\>C was predicted to bind to miRNA-576 at the T variant allele or bind to miRNA-767 at the C allele. Therefore, we speculated that the expression of mTOR depended on the proportions of these two miRNAs or the affinity between miRNA and SNP rs2536 T\>C, which has a growth advantage of immortalized cells and induces neoplastic transformation. It was indicated that disease-associated functional intronic variants may alter mRNA levels of the genes by affecting the transcriptional efficiency, RNA elongation, or splicing [@pone.0071968-Tokuhiro1]--[@pone.0071968-Naukkarinen1]. On the other hand, the SNP rs1034528 G\>C located in the first intron region of the *mTOR* gene was also found to be associated with risk of PCa; however, both rs1034528 G and C alleles were predicted to bind to different transcription factors, respectively, in this region. Therefore, the exact mechanisms of the rs1034528 G\>C underlying the observed PCa risk need additional functional studies.

There is evidence in the literature that each SNP may have a weak effect but the combination of multi-SNPs may present much stronger effects than any of the SNPs. This is particularly true in the present study, in which the haplotype and combined analyses confirmed the multi-SNPs effects in PCa. In the logistic regression model, a locus dose-response was found for the increased PCa risk with the increasing number of adverse genotypes of all studied SNPs. Additionally, we noticed the combined effects was more pronounced among subgroups of age≤69 and BMI≤24 kg/m^2^. These findings agreed with the hypothesis that genetic susceptibility contributes to the risk of developing cancer in those who had an early age onset and minor exposures. Although the interaction between smoking and *mTOR* SNPs was not observed in the present study, we did find an obvious effect of the combined unfavorable genotypes on PCa risk, particularly among subgroups of ever smoker, suggesting that the effect of the tobacco smoke-related carcinogens may also depend on genetic factors.

In the present study, the number of positive findings from the stratified analyses was obviously decreased in the FPRP assessment. There are several possible explanations for the false positive findings. Firstly, some findings in the stratified analyses may be a chance finding due to the limited sample size in the subgroups. Secondly, some missing information and potential confounding factors might result in the false positive associations. Therefore, all positive results should be explained with caution. Extensive evidence from previous epidemiology studies has indicated that several genetic variant and environmental factors are involved in the initiation and development of cancer [@pone.0071968-Liu1]--[@pone.0071968-Zhang2]. We also found the similar interactions by using logistic regression and MDR approaches (**Table S1 in [File S1](#pone.0071968.s001){ref-type="supplementary-material"}**). In the MDR analysis, BMI was found to be the most noteworthy factor in one-factor model; however, the exact mechanisms for the association between BMI and PCa risk have not been established. Possible hypotheses include the effect of hormones, PSA, and adipose-related proteins [@pone.0071968-Freeman1]. In the present study, we found some evidence of the interactions between environmental factor (BMI) and genetic factors (rs17036508 T\>C and rs2536 T\>C), as shown in the best three-factor model, we speculated that those variations might alter the expression of *mTOR* and the subsequent synthesis of adipose-related proteins, but this finding needs to be validated in larger studies.

In summary, the present study investigated the associations between six selected potentially functional *mTOR* SNPs and PCa risk with a relative large sample size. However, several methodological issues and limitations of the present study should be discussed. Firstly, some participants might be misclassified due to the lack of PSA serum information; for example, some silent tumors (stage A1, usually asymptomatic) may have been included as normal controls, which could subsequently bias the results to the null. Secondly, although hormonal, occupational, dietary, inflammation and other factors have been suggested as etiological factors of PCa, we did not adequately documented these covariables for adjustment. Thirdly, only six potentially functional SNPs of *mTOR* were investigated in the present study, which did not cover all variants in the *mTOR* gene. Therefore, additional larger and well-designed studies are warranted to confirm our findings.
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